Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247423 | 0.86 | — | — | |
| SCHEMBL4243991 | 0.81 | GAA (0.59) | — | |
| SCHEMBL3367951 | 0.79 | RAB9A (0.56) | — | |
| SCHEMBL2085892 | 0.76 | RAB9A (0.50) | ALDH1A1 | |
| SCHEMBL4213323 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL2086035 | 0.75 | RAB9A (0.49) | ALDH1A1 | |
| SCHEMBL2086383 | 0.75 | CDK2 (0.45) | — | |
| SCHEMBL2085478 | 0.75 | — | — | |
| SCHEMBL15071112 | 0.71 | CNR2 (0.49) | ALDH1A1 | |
| SCHEMBL2087833 | 0.71 | PTGS1 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040703-B1 | DERIVATIVES OF 2-BENZOYL-IMIDAZOPYRIDINES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2009-10-21 | — | — | EP | claimed |
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | claimed |
| US-7902219-B2 | 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-08 | — | — | US | disclosed |
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | NR4A2, NR4A3, NCOR1 | ALDH1A1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.